Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.44 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046334 | 0.85 | CAPN1 (0.46) | CAPN1CAPN2BMP1FOLH1HTT | |
| SCHEMBL7044862 | 0.85 | BMP1 (0.47) | CAPN1CAPN2BMP1FOLH1HTT | |
| SCHEMBL17666010 | 0.79 | FOLH1 (0.52) | FOLH1HTTMMP2MMP3MMP7 | |
| SCHEMBL28341577 | 0.78 | MAPT (0.60) | FOLH1HDAC6 | |
| SCHEMBL17646323 | 0.78 | MAPT (0.60) | FOLH1HDAC6 | |
| SCHEMBL28341559 | 0.76 | ANPEP (0.62) | FOLH1HTTMMP2HDAC6ANPEP | |
| SCHEMBL17646395 | 0.76 | ANPEP (0.62) | FOLH1HTTMMP2HDAC6ANPEP | |
| Hydrochloric Acid SCHEMBL28344079 | 0.75 | ANPEP (0.61) | FOLH1HTTMMP2HDAC6ANPEP | |
| Hydrochloric Acid SCHEMBL17646405 | 0.75 | ANPEP (0.61) | FOLH1HTTMMP2HDAC6ANPEP | |
| SCHEMBL17646277 | 0.75 | F2 (0.49) | FOLH1MMP2HDAC6ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CAPN1 56/4885CAPN2 62/4885BMP1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.